Anti-inflammatory treatment in schizophrenia

Common polygenic variation contributes to risk of schizophrenia and bipolar disorder

The International Schizophrenia Consortium (2009) · Nature · doi:10.1038/nature08185 · Cited by 4,821 · see citing works

Microglia-mediated neurotoxicity: uncovering the molecular mechanisms

Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110 · see citing works

Microglia: Active sensor and versatile effector cells in the normal and pathologic brain

Hanisch, U.-K., & Kettenmann, H. (2007) · Nature Neuroscience · doi:10.1038/nn1997 · Cited by 3,676 · see citing works

M-1/M-2 Macrophages and the Th1/Th2 Paradigm

Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6166 · Cited by 3,287 · see citing works

Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects

Miller, B. J., Buckley, P., Seabolt, W., Mellor, A., & Kirkpatrick, B. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.013 · Cited by 1,742 · see citing works

Common variants conferring risk of schizophrenia

†Genetic Risk and Outcome in Psychosis (GROUP), Stefansson, H., Ophoff, R. A., Steinberg, S., Andreassen, O. A., Cichon, S., Rujescu, D., Werge, T., Pietiläinen, O. P. H., Mors, O., et al. (2009) · Nature · doi:10.1038/nature08186 · Cited by 1,677 · see citing works

Common variants on chromosome 6p22.1 are associated with schizophrenia

Shi, J., Levinson, D. F., Duan, J., Sanders, A. R., Zheng, Y., Pe’er, I., Dudbridge, F., Holmans, P., Whittemore, A. S., Mowry, B. J., et al. (2009) · Nature · doi:10.1038/nature08192 · Cited by 1,154 · see citing works

Serologic Evidence of Prenatal Influenza in the Etiology of Schizophrenia

Brown, A. S., Begg, M. D., Gravenstein, S., Schaefer, C. A., Wyatt, R. J., Bresnahan, M. A., Babulas, V. P., & Susser, E. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.8.774 · Cited by 1,048 · see citing works

Inflammatory Cytokine Alterations in Schizophrenia: A Systematic Quantitative Review

Potvin, S., Stip, É., Sepehry, A. A., Gendron, A., Bah, R., & Kouassi, É. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.09.024 · Cited by 989 · see citing works

Type 1/Type 2 Immunity in Infectious Diseases

Spellberg, B. J., & Edwards, J. E. (2001) · Clinical Infectious Diseases · doi:10.1086/317537 · Cited by 904 · see citing works

Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders: A Randomized, Placebo-Controlled Trial

Amminger, G. P., Schäfer, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. M., Mackinnon, A., McGorry, P. D., & Berger, G. E. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.192 · Cited by 896 · see citing works

Immunological aspects in the neurobiology of suicide: Elevated microglial density in schizophrenia and depression is associated with suicide

Steiner, J., Bielau, H., Brisch, R., Danos, P., Ullrich, O., Mawrin, C., Bernstein, H.-G., & Bogerts, B. (2008) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.10.013 · Cited by 791 · see citing works

Neopterin as a Marker for Immune System Activation

Murr, C., Widner, B., Wirleitner, B., & Fuchs, D. (2002) · Current Drug Metabolism · doi:10.2174/1389200024605082 · Cited by 737 · see citing works

TLR signaling tailors innate immune responses in human microglia and astrocytes

Jack, C. S., Arbour, N., Manusow, J., Montgrain, V., Blain, M., McCrea, E., Shapiro, A., & Antel, J. P. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.7.4320 · Cited by 734 · see citing works

INCREASED SERUM IL-6 AND IL-1 RECEPTOR ANTAGONIST CONCENTRATIONS IN MAJOR DEPRESSION AND TREATMENT RESISTANT DEPRESSION

Maes, M., Bosmans, E., De Jongh, R., Kenis, G., Vandoolaeghe, E., & Neels, H. (1997) · Cytokine · doi:10.1006/cyto.1997.0238 · Cited by 728 · see citing works

The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression

Müller, N., & Schwarz, M. J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002006 · Cited by 670 · see citing works

Increased cortical kynurenate content in schizophrenia

Schwarcz, R., Rassoulpour, A., Wu, H.-Q., Medoff, D., Tamminga, C. A., & Roberts, R. C. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01078-2 · Cited by 590 · see citing works

Microglia Activation in Recent-Onset Schizophrenia: A Quantitative (R)-[11C]PK11195 Positron Emission Tomography Study

van Berckel, B. N. M., Bossong, M. G., Boellaard, R., Kloet, R. W., Schuitemaker, A., Caspers, E., Luurtsema, G., Windhorst, A. D., Cahn, W., Lammertsma, A. A., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.025 · Cited by 582 · see citing works

Neuroinflammation in Schizophrenia-Related Psychosis: A PET Study

Doorduin, J., de Vries, E. F. J., Willemsen, A. T. M., de Groot, J. C., Dierckx, R., & Klein, H. C. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.066647 · Cited by 561 · see citing works

Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection

Guillemin, G. J., Kerr, S. J., Smythe, G. A., Smith, D. G., Kapoor, V., Armati, P. J., Croitoru‐Lamoury, J., & Brew, B. J. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00498.x · Cited by 541 · see citing works

Prenatal Infection as a Risk Factor for Schizophrenia

Brown, A. S. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj052 · Cited by 540 · see citing works

Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia.

Erhardt, S., Blennow, K., Nordin, C., Skogh, E., Lindström, L., & Engberg, G. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02242-x · Cited by 478 · see citing works

Beneficial Antipsychotic Effects of Celecoxib Add-On Therapy Compared to Risperidone Alone in Schizophrenia

Müller, N., Riedel, M. J., Scheppach, C., Brandstätter, B., Sokullu, S., Krampe, K., Ulmschneider, M., Engel, R. R., Möller, H., & Schwarz, M. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1029 · Cited by 388 · see citing works

Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers

Maes, M. H. J., Bosmans, E., Calabrese, J. R., Smith, R. S., & Meltzer, H. Y. (1995) · Journal of Psychiatric Research · doi:10.1016/0022-3956(94)00049-w · Cited by 385 · see citing works

Microglia Protect Neurons against Ischemia by Synthesis of Tumor Necrosis Factor

Lambertsen, K. L., Clausen, B. H., Babcock, A. A., Gregersen, R., Fenger, C., Nielsen, H. H., Haugaard, L. S., Wirenfeldt, M., Nielsen, M., Dagnæs‐Hansen, F., et al. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.5505-08.2009 · Cited by 364 · see citing works

Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring

Zuckerman, L., & Weiner, I. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2004.08.008 · Cited by 352 · see citing works

Increase in HLA-DR Immunoreactive Microglia in Frontal and Temporal Cortex of Chronic Schizophrenics

Radewicz, K., Garey, L. J., Gentleman, S. M., & Reynolds, R. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.2.137 · Cited by 341 · see citing works

Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs

Maes, M. H. J., Delange, J., Ranjan, R., Meltzer, H. Y., Desnyder, R., Cooremans, W., & Scharpé, S. (1997) · Psychiatry Research · doi:10.1016/s0165-1781(96)02915-0 · Cited by 341 · see citing works

Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia.

Linderholm, K., Skogh, E., Olsson, S., Dahl, M., Holtze, M., Engberg, G., Samuelsson, M., & Erhardt, S. (2012) · Schizophrenia bulletin · doi:10.1093/schbul/sbq086 · Cited by 335 · see citing works

Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia

Peet, M., Brind, J., Ramchand, C. N., Shah, S., & Vankar, G. K. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00083-9 · Cited by 329 · see citing works

Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis

Haack, M., Hinze‐Selch, D., Fenzel, T., Kraus, T., Kühn, M., Schuld, A., & Pollmächer, T. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00021-7 · Cited by 329 · see citing works

A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms

Peet, M., & Horrobin, D. F. (2002) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(01)00048-6 · Cited by 329 · see citing works

Evidence for activation of microglia in patients with psychiatric illnesses

Bayer, T. A., Buslei, R., Havas, L., & Falkai, P. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00545-5 · Cited by 323 · see citing works

A Placebo-Controlled Trial of Omega-3 Fatty Acid (Ethyl Eicosapentaenoic Acid) Supplementation for Residual Symptoms and Cognitive Impairment in Schizophrenia

Fenton, W. S., Dickerson, F., Boronow, J. J., Hibbeln, J. R., & Knable, M. B. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.12.2071 · Cited by 322 · see citing works

The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6

Lin, A., Kenis, G., Bignotti, S., Tura, G. J. B., Jong, R. D., Bosmans, E., Pioli, R., Altamura, C. A., Scharpé, S., & Maes, M. H. J. (1998) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00034-6 · Cited by 321 · see citing works

Randomized, Placebo-Controlled Study of Ethyl-Eicosapentaenoic Acid as Supplemental Treatment in Schizophrenia

Emsley, R. A., Myburgh, C., Oosthuizen, P. P., & van Rensburg, S. J. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.9.1596 · Cited by 306 · see citing works

The Role of Immune System in Schizophrenia

Müller, N., & Schwarz, M. (2010) · Current Immunology Reviews · doi:10.2174/157339510791823673 · Cited by 297 · see citing works

Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial

Akhondzadeh, S., Tabatabaee, M., AMINI, H., Ahmadi-Abhari, S.-A., ABBASI, S., & BEHNAM, B. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2006.11.016 · Cited by 290 · see citing works

Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid?

Ross, B. M., Seguin, J., & Sieswerda, L. E. (2007) · Lipids in Health and Disease · doi:10.1186/1476-511x-6-21 · Cited by 275 · see citing works

The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder.

Drexhage, R. C., Knijff, E. M., Padmos, R. C., Heul-Nieuwenhuijzen, L. V. D., Beumer, W., Versnel, M. A., & Drexhage, H. A. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.144 · Cited by 263 · see citing works

Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin

Ehrenreich, H., Hinze‐Selch, D., Stawicki, S., Aust, C., Knolle-Veentjer, S., Wilms, S., Heinz, G., Erdag, S., Jahn, H., Degner, D., et al. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001907 · Cited by 260 · see citing works

Inflammatory processes in schizophrenia: A promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond

Meyer, U., Schwarz, M., & Müller, N. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.06.003 · Cited by 255 · see citing works

IL-12 production by central nervous system microglia is inhibited by astrocytes

Aloisi, F., Penna, G., Cerase, J., Iglesias, B. M., & Adorini, L. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.4.1604 · Cited by 252 · see citing works

Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment

Müller, N., Krause, D., Dehning, S., Musil, R., Schennach-Wolff, R., Obermeier, M., Möller, H., Klauß, V., Schwarz, M., & Riedel, M. J. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.04.015 · Cited by 251 · see citing works

Prenatal immune activation leads to multiple changes in basal neurotransmitter levels in the adult brain: implications for brain disorders of neurodevelopmental origin such as schizophrenia

Winter, C., Djodari-Irani, A., Sohr, R., Morgenstern, R., Feldon, J., Juckel, G., & Meyer, U. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009206 · Cited by 242 · see citing works

Infections in the CNS During Childhood and the Risk of Subsequent Psychotic Illness: A Cohort Study of More Than One Million Swedish Subjects

Dalman, C., Alle­beck, P., Gunnell, D., Harrison, G. L., Kristensson, K., Lewis, G., Löfving, S., Rasmussen, F. E., Wicks, S., & Karlsson, H. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07050740 · Cited by 242 · see citing works

Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder

Miller, C. L., Llenos, I. C., Dulay, J. R., & Weis, S. (2006) · Brain Research · doi:10.1016/j.brainres.2005.12.056 · Cited by 240 · see citing works

Immune‐inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine

Maes, M. H. J., Meltzer, H. Y., & Bosmans, E. (1994) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1994.tb01527.x · Cited by 237 · see citing works

Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: Identification of subgroups with immune responses and blood–CSF barrier dysfunction

Bechter, K., Reiber, H., Herzog, S., Fuchs, D., Tumani, H., & Maxeiner, H. G. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2009.08.008 · Cited by 230 · see citing works

The macrophage-T-lymphocyte theory of schizophrenia: Additional evidence

Smith, R. S., & Maes, M. H. J. (1995) · Medical Hypotheses · doi:10.1016/0306-9877(95)90062-4 · Cited by 222 · see citing works

Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease

Mittleman, B. B., Castellanos, F. X., Jacobsen, L. K., Rapoport, J. L., Swedo, S. E., & Shearer, G. M. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.6.2994 · Cited by 218 · see citing works

Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types

Heyes, M. P., Chen, C. Y., Major, E. O., & Saito, K. (1997) · Biochemical Journal · doi:10.1042/bj3260351 · Cited by 215 · see citing works

Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy

Bernstein, H., Steiner, J. H., & Bogerts, B. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.59 · Cited by 189 · see citing works

Th1, Th2 and Th3 cytokine alteration in schizophrenia

Kim, Y., Myint, A.-M., Lee, B.-H., Han, C.-S., Lee, H., Kim, D.-J., & Leonard, B. E. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.05.047 · Cited by 187 · see citing works

Effects of antipsychotic drugs on cytokine networks

Pollmächer, T., Haack, M., Schuld, A., Kraus, T., & Hinze‐Selch, D. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(00)00032-7 · Cited by 180 · see citing works

In vivo immunomodulatory effects of clozapine in schizophrenia

Maes, M. H. J., Bosmans, E., Kenis, G., Jong, R. D., Smith, R. S., & Meltzer, H. Y. (1997) · Schizophrenia Research · doi:10.1016/s0920-9964(97)00057-1 · Cited by 178 · see citing works

Potential Roles of Histones in Host Defense as Antimicrobial Agents

Kawasaki, H., & Iwamuro, S. (2008) · Infectious Disorders - Drug Targets · doi:10.2174/1871526510808030195 · Cited by 177 · see citing works

Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C]DAA1106

Takano, A., Arakawa, R., Ito, H., Tateno, A., Takahashi, H., Matsumoto, R., Okubo, Y., & Suhara, T. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000313 · Cited by 174 · see citing works

Inhibition of COX‐2 reduces the age‐dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat

Casolini, P., Catalani, A., Zuena, A. R., & Angelucci, L. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10192 · Cited by 174 · see citing works

Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients

Wilke, I., Arolt, V., Rothermundt, M., Weitzsch, C., Hornberg, M., & Kirchner, H. (1996) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02190280 · Cited by 170 · see citing works

Effects of the diet on brain neurotransmitters

Fernstrom, J. D. (1977) · Metabolism · doi:10.1016/0026-0495(77)90057-9 · Cited by 159 · see citing works

Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF

Rothermundt, M., Falkai, P., Ponath, G. D., Abel, S., Bürkle, H., Diedrich, M., Hetzel, G., Peters, M., Siegmund, A., Pedersen, A., et al. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001548 · Cited by 148 · see citing works

COX-2 inhibition as a treatment approach in schizophrenia: Immunological considerations and clinical effects of celecoxib add-on therapy

M�ller, N., Ulmschneider, M., Scheppach, C., Schwarz, M., Ackenheil, M., M�ller, H.-J., Gruber, R., & Riedel, M. J. (2004) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-004-0478-1 · Cited by 143 · see citing works

Celecoxib Augmentation of Continuously Ill Patients with Schizophrenia

Rapaport, M. H., Delrahim, K. K., Bresee, C. J., Maddux, R. E., Ahmadpour, O. A., & Dolnak, D. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.02.024 · Cited by 137 · see citing works

Cytokine Changes and Tryptophan Metabolites in Medication-Naïve and Medication-Free Schizophrenic Patients

Kim, Y., Myint, A.-M., Verkerk, R. M., Scharpé, S., Steinbusch, H. W. M., & Leonard, B. E. (2009) · Neuropsychobiology · doi:10.1159/000213565 · Cited by 136 · see citing works

Clinical effects of COX?2 inhibitors on cognition in schizophrenia

M�ller, N., Riedel, M. J., Schwarz, M., & Engel, R. R. (2004) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-004-0548-4 · Cited by 135 · see citing works

Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer’s disease in a sex-dimorphic pattern

Melnikova, T., Savonenko, A. V., Wang, Q., Liang, X., Hand, T. A., Wu, L., Kaufmann, W. E., Vehmas, A. K., & Andreasson, K. I. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.05.001 · Cited by 134 · see citing works

Cellular immunity in schizophrenic patients before and during neuroleptic treatment

Müller, N., Ackenheil, M., Hofschuster, E., Mempel, W., & Eckstein, R. (1991) · Psychiatry Research · doi:10.1016/0165-1781(91)90072-w · Cited by 130 · see citing works

Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment

Arolt, V., Rothermundt, M., Wandinger, K.-P., & Kirchner, H. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000650 · Cited by 128 · see citing works

Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia

Müller, N., Empl, M., Riedel, M. J., Schwarz, M., & Ackenheil, M. (1997) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02922260 · Cited by 127 · see citing works

Neural injury following stroke: are Toll‐like receptors the link between the immune system and the CNS?

Downes, C., & Crack, P. J. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00864.x · Cited by 122 · see citing works

Kynurenate production by cultured human astrocytes

Kiss, C., Ceresoli‐Borroni, G., Guidetti, P., Zielke, C. L., Zielke, H. R., & Schwarcz, R. M. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-002-0770-z · Cited by 121 · see citing works

Quantitative analysis of activated microglia, ramified and damage of processes in the frontal and temporal lobes of chronic schizophrenics.

Wierzba‐Bobrowicz, T., Lewandowska, E., Lechowicz, W., Stępień, T., & Pasennik, E. (2005) · PubMed · Cited by 113 · see citing works

Childhood central nervous system infections and risk for schizophrenia

Koponen, H., Rantakallio, P. T., Veijola, J. M., Jones, P. B., Jokelainen, J. J., & Isohanni, M. K. (2004) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-004-0485-2 · Cited by 112 · see citing works

Cytokines production in chronic schizophrenia patients with or without paranoid behaviour

Cazzullo, C. L., Scarone, S., GRASSI, B., Vismara, C. S., Trabattoni, D., Clerici, M., & Clerici, M. (1998) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(98)00059-1 · Cited by 108 · see citing works

Aberrant prostaglandin synthase 2 expression defines an antigen-presenting cell defect for insulin-dependent diabetes mellitus

Litherland, S. A., Xie, X. T., Hutson, A. D., Wasserfall, C. H., Whittaker, D. S., She, J., Hofig, A., Dennis, M., Fuller, K. E., Cook, R. W., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci4852 · Cited by 108 · see citing works

The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view

Müller, N., & Schwarz, M. (2007) · Springer eBooks · doi:10.1007/978-3-211-73574-9_33 · Cited by 107 · see citing works

Immunological Dysfunction in Schizophrenia: A Systematic Approach

Rothermundt, M., Arolt, V., Weitzsch, C., Eckhoff, D., & Kirchner, H. (1998) · Neuropsychobiology · doi:10.1159/000026501 · Cited by 104 · see citing works

Elevated circulating levels of IL-6 in schizophrenia

Naudin, J., Mège, J. L., Azorin, J., & Dassa, D. (1996) · Schizophrenia Research · doi:10.1016/0920-9964(96)00014-x · Cited by 104 · see citing works

Impaired monocyte activation in schizophrenia

Müller, N., Wagner, J. K., Krause, D., Weidinger, E., Wildenauer, A., Obermeier, M., Dehning, S., Gruber, R., & Schwarz, M. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2011.12.049 · Cited by 97 · see citing works

The effects of eicosapentaenoic acid in tardive dyskinesia: A randomized, placebo-controlled trial

Emsley, R. A., Niehaus, D. J. H., Koen, L., Oosthuizen, P. P., Turner, H. J., Carey, P. D., van Rensburg, S. J., Maritz, J. S., & Murck, H. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.03.023 · Cited by 97 · see citing works

Decreased levels of soluble intercellular adhesion Molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients

Schwarz, M., Riedel, M. J., Ackenheil, M., & Müller, N. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00206-1 · Cited by 96 · see citing works

Increased frequency of activated lymphocytes in the cerebrospinal fluid of patients with acute schizophrenia

Nikkilä, H. V., Müller, K., Ahokas, A., Rimón, R., & Andersson, L. C. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00218-2 · Cited by 95 · see citing works

Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia

Wüstenberg, T., Begemann, M., Bartels, C., Gefeller, O., Stawicki, S., Hinze‐Selch, D., Mohr, A., Falkai, P., Aldenhoff, J., Knauth, M., et al. (2010) · Molecular Psychiatry · doi:10.1038/mp.2010.51 · Cited by 93 · see citing works

Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice

Mizoguchi, H., Takuma, K., Fukakusa, A., Ito, Y., Nakatani, A., Ibi, D., Kim, H., & Yamada, K. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0955-0 · Cited by 92 · see citing works

Cellular and Humoral Immune System in Schizophrenia: A Conceptual Re-Evaluation

Müller, N., Riedel, M. J., Ackenheil, M., & Schwarz, M. (2000) · The World Journal of Biological Psychiatry · doi:10.3109/15622970009150588 · Cited by 91 · see citing works

Serum interleukin-6 in schizophrenic patients

Shintani, F., Kanba, S., MARUO, N., Nakaki, T., Nibuya, M., Suzuki, E., Kinoshita, N., & Yagi, G. (1991) · Life Sciences · doi:10.1016/0024-3205(91)90112-o · Cited by 89 · see citing works

T-cell subsets in schizophrenia: a comparison between drug-naive first episode patients and chronic schizophrenic patients

Sperner‐Unterweger, B., Whitworth, A. B., Kemmler, G., Hilbe, W., Thaler, J., Weiß, G., & Fleischhacker, W. W. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00175-3 · Cited by 86 · see citing works

Fibrin degradation products in post mortem brain tissue of schizophrenics: a possible marker for underlying inflammatory processes

Körschenhausen, D. A., Hampel, H. J., Ackenheil, M., Penning, R., & Müller, N. (1996) · Schizophrenia Research · doi:10.1016/0920-9964(95)00073-9 · Cited by 86 · see citing works

Inflammation in Schizophrenia

Müller, N., Myint, A.-M., & Schwarz, M. (2012) · Advances in protein chemistry and structural biology · doi:10.1016/b978-0-12-398314-5.00003-9 · Cited by 84 · see citing works

Reviewing the Role of DNA (Cytosine-5) Methyltransferase Overexpression in the Cortical GABAergic Dysfunction Associated with Psychosis Vulnerability

Dong, E., Grayson, D. R., Guidotti, A., Ruzicka, W. B., Veldić, M., & Costa, E. (2007) · Epigenetics · doi:10.4161/epi.2.1.4063 · Cited by 84 · see citing works

Kynurenine Disposition in Blood and Brain of Mice: Effects of Selective Inhibitors of Kynurenine Hydroxylase and of Kynureninase

Chiarugi, A., Carpenedo, R., & Moroni, F. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67020692.x · Cited by 84 · see citing works

Monocytic, Th1 and Th2 Cytokine Alterations in the Pathophysiology of Schizophrenia

Na, K.-S., & Kim, Y. (2007) · Neuropsychobiology · doi:10.1159/000111535 · Cited by 82 · see citing works

Prostaglandin-mediated control of rat brain kynurenic acid synthesis – opposite actions by COX-1 and COX-2 isoforms

Schwieler, L., Erhardt, S., Erhardt, C., & Engberg, G. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0231-y · Cited by 81 · see citing works

The Risk for Schizophrenia From Childhood and Adult Infections

Brown, A. S. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07101637 · Cited by 80 · see citing works

Associations between Chlamydophila infections, schizophrenia and risk of HLA-A10

Fellerhoff, B., Laumbacher, B., Mueller, N., Gu, S., & Wank, R. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001925 · Cited by 78 · see citing works

Serum interleukin-18 levels are elevated in schizophrenia

Tanaka, K. F., Shintani, F., 藤井, 康., Yagi, G., & Asai, M. (2000) · Psychiatry Research · doi:10.1016/s0165-1781(00)00196-7 · Cited by 78 · see citing works

Maternal Recall of Pregnancy History: Accuracy and Bias in Schizophrenia Research

Buka, S. L., Goldstein, J. M., Seidman, L. J., & Tsuang, M. T. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033457 · Cited by 77 · see citing works

Urinary excretion of bioterin and neopterin in psychiatric disorders

Duch, D. S., Woolf, J. H., Nichol, C. A., Davidson, J. R. T., & Garbutt, J. C. (1984) · Psychiatry Research · doi:10.1016/0165-1781(84)90090-8 · Cited by 75 · see citing works

Kynurenic Acid And Schizophrenia

Erhardt, S., Schwieler, L., & Engberg, G. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0135-0_18 · Cited by 74 · see citing works

Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain

Ceresoli‐Borroni, G., Rassoulpour, A., Wu, H., Guidetti, P., & Schwarcz, R. M. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-005-0432-z · Cited by 72 · see citing works

Increase in Expression of Adhesion Molecule Receptors on T Helper Cells During Antipsychotic Treatment and Relationship to Blood-Brain Barrier Permeability in Schizophrenia

ller, N. M. ⁄., Riedel, M. J., Hadjamu, M., Schwarz, M., Ackenheil, M., & Gruber, R. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.4.634 · Cited by 72 · see citing works

Increased complement classical and mannan-binding lectin pathway activities in schizophrenia

Mayilyan, K. R., Arnold, J. N., Presanis, J. S., Soghoyan, A. F., & Sim, R. B. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.06.051 · Cited by 71 · see citing works

Decreased T cellular immune response in schizophrenic patients

Riedel, M., Spellmann, I., Schwarz, M., Strassnig, M., SIKORSKI, C., MOLLER, H., & Müller, N. (2006) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2005.11.007 · Cited by 71 · see citing works

LFA-1 Contributes to Signal I of T-Cell Activation and to the Production of Th1 Cytokines

Varga, G., Nippe, N., Balkow, S., Peters, T., Wild, M. K., Seeliger, S., Beissert, S., Krummen, M., Roth, J., Sunderkötter, C. H., et al. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.398 · Cited by 67 · see citing works

Increased Th1 and Th2 immune reactivity with relative Th2 dominance in patients with acute exacerbation of schizophrenia.

Avguštin, B., Wraber, B., & Tavčar, R. (2005) · PubMed · Cited by 65 · see citing works

Factors Influencing Serum Neopterin Concentrations in a Population of Blood Donors

Schennach, H., Murr, C., Gächter, E., Mayersbach, P., Schönitzer, D., & Fuchs, D. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.4.643 · Cited by 64 · see citing works

The Effects of Memantine on Prepulse Inhibition

Swerdlow, N. R., van Bergeijk, D. P., Bergsma, F., Weber, E., & Talledo, J. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.7 · Cited by 62 · see citing works

Acute phase proteins in male Chinese schizophrenic patients in Singapore

Chong-Thim, W., Tsoi, W. F., & Saha, N. (1996) · Schizophrenia Research · doi:10.1016/s0920-9964(96)00037-0 · Cited by 62 · see citing works

Inflammation in psychotic disorders: A population-based study

Suvisaari, J., Loo, B.-M., Saarni, S. E., Haukka, J. K., Perälä, J., Saarni, S. I., Viertiö, S., Partti, K., Lönnqvist, J. K., & Jula, A. (2011) · Psychiatry Research · doi:10.1016/j.psychres.2011.07.006 · Cited by 57 · see citing works

Oxidative stress and neopterin abnormalities in schizophrenia: A longitudinal study

Chittiprol, S., Venkatasubramanian, G., Neelakantachar, N., Babu, S. V. S., Reddy, N. A., Shetty, K. T., & Gangadhar, B. N. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2009.09.002 · Cited by 57 · see citing works

Reduction of Symptoms by Valacyclovir in Cytomegalovirus-Seropositive Individuals With Schizophrenia

Dickerson, F., Boronow, J. J., Stallings, C. R., Origoni, A. E., & Yolken, R. H. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.12.2234 · Cited by 56 · see citing works

Childhood meningitis, brain maturation and the risk of psychosis*

Gattaz, W. F., Abrah�o, A. L., & Foccacia, R. (2004) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-004-0431-3 · Cited by 54 · see citing works

A role for inflammatory mediators in the IL-18 mediated attenuation of LTP in the rat dentate gyrus

Cumiskey, D., Curran, B. P., Herron, C. E., & O'Connor, J. J. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.03.006 · Cited by 50 · see citing works

Persistently increased serum soluble interleukin-2 receptors in continuously ill patients with schizophrenia

Bresee, C. J., & Rapaport, M. H. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709000315 · Cited by 48 · see citing works

Omega-3 polyunsaturated fatty acids in the treatment of schizophrenia.

Peet, M. (2008) · PubMed · Cited by 46 · see citing works

Possible anti-catatonic effects of minocycline in patients with schizophrenia

Ahuja, N., & Carroll, B. T. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.01.018 · Cited by 41 · see citing works

Relationship between immune and behavioral measures in schizophrenia

van Kammen, D. P., McAllister, C. G., & Kelley, M. E. (1997) · Key topics in brain research · doi:10.1007/978-3-7091-6870-7_7 · Cited by 39 · see citing works

Hyposensitivity to foreign protein in schizophrenic patients

Molholm, H. B. (1942) · Psychiatric Quarterly · doi:10.1007/bf01573918 · Cited by 38 · see citing works

Immunological Treatment Options for Schizophrenia

Müller, N., Myint, A.-M., & Schwarz, M. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112800784826 · Cited by 34 · see citing works

Medical and Psychiatric Comorbidity Over the Course of Life

Kolodziej, M. (2006) · Psychiatric Services · doi:10.1176/appi.ps.57.10.1534 · Cited by 34 · see citing works

Zur klinischen Relevanz der Wirkung von Clozapin auf die Freisetzung von Zytokinen und löslichen Zytokinrezeptoren

Pollmächer, T., Schuld, A., Kraus, T., Haack, M., & Hinze‐Selch, D. (2001) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/s-2001-16533 · Cited by 31 · see citing works

Measurement of neopterin, kynurenine and tryptophan in sera of schizophrenic patients

Sperner‐Unterweger, B., Miller, C., Holzner, B., Widner, B., Fleischhacker, W. W., & Fuchs, D. (1999) · Key topics in brain research · doi:10.1007/978-3-7091-6404-4_12 · Cited by 29 · see citing works

A double-blind trial of adjunctive azithromycin in individuals with schizophrenia who are seropositive for Toxoplasma gondii

Dickerson, F., Stallings, C. R., Boronow, J. J., Origoni, A. E., & Yolken, R. H. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.05.005 · Cited by 29 · see citing works

Increased serum neopterin levels in acutely ill and recovered schizophrenic patients

Korte, S., Arolt, V., Peters, M., Weitzsch, C., Rothermundt, M., & Kirchner, H. (1998) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00037-1 · Cited by 28 · see citing works

The Differential Role of L-Selectin and ICAM-1 in Th1-Type and Th2-Type Contact Hypersensitivity

Ogawa, A., Yoshizaki, A., Yanaba, K., Ogawa, F., Hara, T., Muroi, E., Takenaka, M., Shimizu, K., Hasegawa, M., Fujimoto, M., et al. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.25 · Cited by 26 · see citing works

Die Wirkung der Neuroleptica-Behandlung auf die Antikörperbildung

Özek, M., Töreci, K., Akkök, I., & Güvener, Z. (1971) · Psychopharmacology · doi:10.1007/bf02419063 · Cited by 26 · see citing works

C3 and C6 Complement Types in Schizophrenia

Rudduck, C., Beckman, L. E., FRANZÉN, G., & m, L. L. O. (1985) · Human Heredity · doi:10.1159/000153555 · Cited by 22 · see citing works

Immunomodulatory Effects of Neuroleptics to the Cytokine System and the Cellular Immune System in Schizophrenia

Müller, N., Riedel, M. J., Schwarz, M., Gruber, R., & Ackenheil, M. (1997) · Key topics in brain research · doi:10.1007/978-3-7091-6870-7_8 · Cited by 20 · see citing works

Psychiatry, Psychoimmunology, and Viruses

(1999) · Key topics in brain research · doi:10.1007/978-3-7091-6404-4 · Cited by 19 · see citing works

Double blind trial of adjunctive valacyclovir in individuals with schizophrenia who are seropositive for cytomegalovirus

Dickerson, F., Stallings, C. R., Boronow, J. J., Origoni, A. E., Sullens, A., & Yolken, R. H. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.10.007 · Cited by 19 · see citing works

Current Update in Psychoimmunology

Wieselmann, G. (1997) · Key topics in brain research · doi:10.1007/978-3-7091-6870-7 · Cited by 16 · see citing works

Short-Term Improvement by Minocycline Added to Olanzapine Antipsychotic Treatment in Paranoid Schizophrenia

Chaves, C., Zuardi, A. W., de Marque, C. R., Chaudhry, I. B., Husain, N., Aslam, F., Oliveira, J. P., Ana, L. W., Kato, M., Dursun, S. M., et al. (2009) · Cited by 11 · see citing works

[An electron microscopic study of typical lymphocytes and atypical cells of peripheral blood in patients with schizophrenia].

Pd, B. (2008) · PubMed · Cited by 4 · see citing works

Stress and neuroinflammation: a systematic review of the effects of stress on microglia and the implications for mental illness

Calcia, M., Bonsall, D. R., Bloomfield, P. S., Selvaraj, S., Barichello, T., & Howes, O. D. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4218-9 · Cited by 710 · see citing works

Altering the course of schizophrenia: progress and perspectives

Millan, M. J., Andrieux, A., Bartzokis, G., Cadenhead, K., Dazzan, P., Fusar-Poli, P., Gallinat, J., Giedd, J., Grayson, D. R., Heinrichs, M., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.28 · Cited by 516 · see citing works

Beyond the association. T oxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta‐analysis

Sutterland, A. L., Fond, G. B., Kuin, A., Koeter, M. W. J., Lutter, R., van Gool, T., Yolken, R. H., Szöke, A., Leboyer, M., & de Haan, L. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12423 · Cited by 439 · see citing works

Negative symptoms of schizophrenia: Clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment

Millan, M. J., Fone, K. C. F., Steckler, T., & Horan, W. P. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.03.008 · Cited by 354 · see citing works

Dysregulation of kynurenine metabolism is related to proinflammatory cytokines, attention, and prefrontal cortex volume in schizophrenia

Kindler, J., Lim, C. K., Weickert, C., Boerrigter, D., Galletly, C., Liu, D., Jacobs, K. R., Balzan, R., Bruggemann, J. M., O'Donnell, M., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0401-9 · Cited by 267 · see citing works

Inflammation and the two-hit hypothesis of schizophrenia

Feigenson, K. A., Kusnecov, A., & Silverstein, S. M. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.11.006 · Cited by 280 · see citing works

Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A “central hub” in schizophrenia pathophysiology?

Steullet, P., Cabungcal, J. H., Monin, A., Dwir, D., O'Donnell, P., Cuenod, M., & Do, K. Q. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2014.06.021 · Cited by 262 · see citing works

The association between first-episode psychosis and abnormal glycaemic control: systematic review and meta-analysis

Perry, B. I., McIntosh, G., Weich, S., Singh, S. P., & Rees, K. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30262-0 · Cited by 227 · see citing works

On inflammatory hypothesis of depression: what is the role of IL-6 in the middle of the chaos?

Roohi, E., Jaafari, N., & Hashemian, F. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02100-7 · Cited by 235 · see citing works

Suicide and Microglia: Recent Findings and Future Perspectives Based on Human Studies

Suzuki, H., Ohgidani, M., Kuwano, N., Chrétien, F., Lorin de la Grandmaison, G., Onaya, M., Tominaga, I., Setoyama, D., Kang, D., Mimura, M., et al. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00031 · Cited by 198 · see citing works

Pathophysiological Roles of Cyclooxygenases and Prostaglandins in the Central Nervous System

Yagami, T., Koma, H., & Yamamoto, Y. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9355-3 · Cited by 191 · see citing works

Inflammation in schizophrenia: A question of balance

Leza, J. C., García‐Bueno, B., Bioque, M., Arango, C., Parellada, M., Kim, Q., O’Donnell, P., & Bernardo, M. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.05.014 · Cited by 183 · see citing works

Development of a blood-based molecular biomarker test for identification of schizophrenia before disease onset

Chan, M. K., Krebs, M., Cox, D., Guest, P. C., Yolken, R. H., Rahmoune, H., Rothermundt, M., Steiner, J. H., Leweke, F. M., van Beveren, N. J. M., et al. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.91 · Cited by 155 · see citing works

Prevalence of anti-N-methyl- d -aspartate (NMDA) receptor antibodies in patients with schizophrenia and related psychoses: a systematic review and meta-analysis

Pollak, T. A., McCormack, R., Peakman, M., Nicholson, T. R., & David, A. S. (2013) · Psychological Medicine · doi:10.1017/s003329171300295x · Cited by 155 · see citing works

Astrogliopathology

Verkhratsky, A., Rodriguez, J. J., & Steardo, L. (2013) · The Neuroscientist · doi:10.1177/1073858413510208 · Cited by 146 · see citing works

Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia

Anderson, G., Berk, M., Dodd, S., Bechter, K., Altamura, A. C., Dell’Osso, B. M., Kanba, S., Monji, A., Fatemi, S. H., Buckley, P. F., et al. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.10.008 · Cited by 140 · see citing works

Adjunctive use of anti-inflammatory drugs for schizophrenia: A meta-analytic investigation of randomized controlled trials

Cho, M., Lee, T. Y., Kwak, Y. B., Yoon, Y. B., Kim, M., & Kwon, J. S. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419835028 · Cited by 128 · see citing works

Effects of inflammation on the kynurenine pathway in schizophrenia—a systematic review

Pedraz-Petrozzi, B., Elyamany, O., Rummel, C., & Mulert, C. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-1721-z · Cited by 119 · see citing works

Eicosanoids Derived From Arachidonic Acid and Their Family Prostaglandins and Cyclooxygenase in Psychiatric Disorders

Yui, K., Imataka, G., Nakamura, H., Ohara, N., & Naito, Y. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666151102103305 · Cited by 118 · see citing works

Inflammation in Schizophrenia: Cytokine Levels and Their Relationships to Demographic and Clinical Variables

Lee, E., Hong, S., Martin, A. S., Eyler, L. T., & Jeste, D. V. (2016) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2016.09.009 · Cited by 113 · see citing works

Interleukin-6 in Schizophrenia—Is There a Therapeutic Relevance?

Borovčanin, M., Jovanović, I., Radosavljevic, G. D., Pantic, J. M., Janicijevic, S. M., Arsenijević, N., & Lukić, M. L. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00221 · Cited by 91 · see citing works

The Cross-Talk Between the Dopaminergic and the Immune System Involved in Schizophrenia

Vidal, P. M., & Pacheco, R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00394 · Cited by 89 · see citing works

Inflammation, Antipsychotic Drugs, and Evidence for Effectiveness of Anti-inflammatory Agents in Schizophrenia

Pandurangi, A. K., & Buckley, P. F. (2019) · Current topics in behavioral neurosciences · doi:10.1007/7854_2019_91 · Cited by 76 · see citing works

Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study

Martinuzzi, E., Barbosa, S., Daoudlarian, D., Ali, W. B. H., Gilet, C., Fillatre, L., Khalfallah, O., Troudet, R., Jamain, S., Fond, G. B., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-018-0366-5 · Cited by 74 · see citing works

The role of microglia in neuropsychiatric disorders and suicide

Brisch, R., Wojtylak, S., Saniotis, A., Steiner, J. H., Gos, T., Kumaratilake, J., Henneberg, M., & Wolf, R. J. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-021-01334-z · Cited by 71 · see citing works

Paliperidone reverts Toll-like receptor 3 signaling pathway activation and cognitive deficits in a maternal immune activation mouse model of schizophrenia

MacDowell, K. S., Munarriz‐Cuezva, E., Caso, J. R., Madrigal, J. L. M., Zabala, A., Meana, J. J., García‐Bueno, B., & Leza, J. C. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.12.025 · Cited by 67 · see citing works

Clinical Staging in Psychiatry

Berger, G. (2019) · Cambridge University Press eBooks · doi:10.1017/9781139839518 · Cited by 64 · see citing works

Peripheral Biomarkers for First-Episode Psychosis—Opportunities from the Neuroinflammatory Hypothesis of Schizophrenia

Trovão, N., Prata, J., von Doellinger, O., Santos, S. G., Barbosa, M. A., & Coelho, R. C. (2019) · Psychiatry Investigation · doi:10.30773/pi.2018.12.19.1 · Cited by 52 · see citing works

Biotyping in psychosis: using multiple computational approaches with one data set

Tamminga, C. A., Clementz, B. A., Pearlson, G. D., Keshavan, M. S., Gershon, E. S., Ivleva, E. I., McDowell, J. E., Meda, S. A., Keedy, S., Calhoun, V. D., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00849-8 · Cited by 48 · see citing works

Refining and integrating schizophrenia pathophysiology – Relevance of the allostatic load concept

Misiak, B., Frydecka, D., Zawadzki, M., Krefft, M., & Kiejna, A. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.06.004 · Cited by 47 · see citing works

Behavioral sequelae of astrocyte dysfunction: focus on animal models of schizophrenia

Xia, M., Abazyan, S., Jouroukhin, Y., & Pletnikov, M. V. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.10.044 · Cited by 46 · see citing works

Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials

Marini, S., Berardis, D. D., Vellante, F., Santacroce, R., Orsolini, L., Valchera, A., Girinelli, G., Carano, A., Fornaro, M., Gambi, F., et al. (2016) · Mediators of Inflammation · doi:10.1155/2016/3476240 · Cited by 44 · see citing works

Importance of kynurenine 3-monooxygenase for spontaneous firing and pharmacological responses of midbrain dopamine neurons: Relevance for schizophrenia

Tufvesson‐Alm, M., Schwieler, L., Schwarcz, R. M., Goiny, M., Erhardt, S., & Engberg, G. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.06.003 · Cited by 40 · see citing works

Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms

Schmitt, A., Martins‐de‐Souza, D., Akbarian, S., Cassoli, J. S., Ehrenreich, H., Fischer, A., Fonteh, A. N., Gattaz, W. F., Gawlik, M., Gerlach, M., et al. (2016) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2016.1224929 · Cited by 41 · see citing works

Peripheral Blood Leukocyte RNA-Seq Identifies a Set of Genes Related to Abnormal Psychomotor Behavior Characteristics in Patients with Schizophrenia

Zhang, Y., You, X., Li, S.-W., Long, Q., Zhu, Y., Teng, Z., & Zeng, Y. (2020) · Medical Science Monitor · doi:10.12659/msm.922426 · Cited by 36 · see citing works

Galantamine-Memantine Combination and Kynurenine Pathway Enzyme Inhibitors in the Treatment of Neuropsychiatric Disorders

Bai, M. Y., Lovejoy, D. B., Guillemin, G. J., Kozak, R., Stone, T. W., & Koola, M. M. (2021) · Complex Psychiatry · doi:10.1159/000515066 · Cited by 34 · see citing works

Associations between sleep quality and inflammatory markers in patients with schizophrenia

Fang, S., Suzuki, K., Lim, C. L., Chung, M.-S., Ku, P., & Chen, L. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.09.032 · Cited by 33 · see citing works

Kynurenine and Tryptophan Levels in Patients With Schizophrenia and Elevated Antigliadin Immunoglobulin G Antibodies

Okusaga, O. O., Fuchs, D., Reeves, G. M., Giegling, I., Hartmann, A. M., Konte, B., Friedl, M., Groer, M. E., Cook, T. B., Stearns‐Yoder, K. A., et al. (2016) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000352 · Cited by 29 · see citing works

Minocycline alleviates behavioral deficits and inhibits microglial activation induced by intrahippocampal administration of Granulocyte–Macrophage Colony-Stimulating Factor in adult rats

Zhu, F., Liu, Y., Zhao, J., & Zheng, Y. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.01.021 · Cited by 29 · see citing works

GABAergic system impairment in the hippocampus and superior temporal gyrus of patients with paranoid schizophrenia: A post-mortem study

Steiner, J. H., Brisch, R., Schiltz, K., Dobrowolny, H., Mawrin, C., Krzyżanowska, M., Bernstein, H., Jankowski, Z., Braun, K., Schmitt, A., et al. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.02.018 · Cited by 29 · see citing works

Molecular hydrogen: an overview of its neurobiological effects and therapeutic potential for bipolar disorder and schizophrenia

Ghanizadeh, A. J., & Berk, M. (2013) · Medical Gas Research · doi:10.1186/2045-9912-3-11 · Cited by 28 · see citing works

The immune system and schizophrenia: an update for clinicians

Upthegrove, R., & Barnes, N. M. (2014) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.113.011452 · Cited by 26 · see citing works

The effect of antipsychotic drugs on nonspecific inflammation markers in the first episode of schizophrenia

Stefanović, V., Mihajlović, G., Nenadović, M., Đukić-Dejanović, S., Borovčanin, M., & Trajkovic, G. (2015) · Vojnosanitetski pregled · doi:10.2298/vsp140526016s · Cited by 24 · see citing works

Associated illness severity in schizophrenia and diabetes mellitus: A systematic review

Perry, B. I., Salimkumar, D., GREEN, D. J., Meakin, A., Gibson, A., Mahajan, D., Tahir, T. A., & Singh, S. P. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.06.027 · Cited by 24 · see citing works

Emerging therapeutic targets for schizophrenia: a framework for novel treatment strategies for psychosis

Sonnenschein, S. F., & Grace, A. A. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1849144 · Cited by 23 · see citing works

Association of the kynurenine pathway metabolites with clinical, cognitive features and IL-1β levels in patients with schizophrenia spectrum disorder and their siblings

Noyan, H., Erdağ, E., Tüzün, E., Yaylım, İ., Küçükhüseyin, Ö., Hakan, M. T., Gülöksüz, S., Rutten, B. P. F., Saka, M. C., Atbaşoğlu, C., et al. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.01.014 · Cited by 23 · see citing works

Tumor Necrosis Factor-alpha (TNF-α) −238 G/A Polymorphism Is Associated with the Treatment Resistance and Attempted Suicide in Schizophrenia

Aytaç, H. M., Özdilli, K., Tunçel, F. C., Pehlıvan, M., & Pehlıvan, S. (2020) · Immunological Investigations · doi:10.1080/08820139.2020.1832115 · Cited by 20 · see citing works

Intestinal tryptophan metabolism in disease prevention and swine production

Hu, Z., Feng, L., Jiang, Q., Wang, W., Tan, B., Tang, X., & Yin, Y. (2023) · Animal nutrition · doi:10.1016/j.aninu.2023.08.002 · Cited by 19 · see citing works

Promoter Polymorphisms of TNF-α Gene as a Risk Factor for Schizophrenia

Suchanek-Raif, R., Raif, P., Kowalczyk, M., Paul-Samojedny, M., Kucia, K. A., Merk, W., & Kowalski, J. (2018) · Archives of Medical Research · doi:10.1016/j.arcmed.2018.09.007 · Cited by 19 · see citing works

Transcriptomic signatures of schizophrenia revealed by dopamine perturbation in an ex vivo model

Duan, J., Göring, H., Sanders, A., Moy, W., Freda, J., Drigalenko, E. I., Kos, M. Z., He, D., Gejman, P., Gejman, P., et al. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0216-5 · Cited by 18 · see citing works

Serum IL-18 level, clinical symptoms and IL-18-607A/C polymorphism among chronic patients with schizophrenia in a Chinese Han population

Zhang, X. Y., Tan, Y., Chen, D., Tan, S., Malouta, M. Z., Bernard, J. D., Combs, J. L., Bhatti, S., Davis, M. C., Kosten, T. R., et al. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2016.03.002 · Cited by 18 · see citing works

A machine learning approach on whole blood immunomarkers to identify an inflammation-associated psychosis onset subgroup

Enrico, P., Delvecchio, G., Turtulici, N., Aronica, R., Pigoni, A., Squarcina, L., Villa, F. M., Perlini, C., Rossetti, M. G., Bellani, M., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01911-1 · Cited by 17 · see citing works

Multianalyte markers of schizophrenia and bipolar disorder: A preliminary study

Dickerson, F., Schroeder, J. R., Stallings, C. R., Origoni, A. E., Bahn, S., & Yolken, R. H. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.08.003 · Cited by 16 · see citing works

The relationship between psychopathology and cognitive functions with cytokines in clinically stable patients with schizophrenia

Ergün, S., Yanartaş, Ö., Kandemir, G., Yaman, A. E., Yıldız, M., Haklar, G., & Sayar, K. (2017) · Psychiatry and Clinical Psychopharmacology · doi:10.1080/24750573.2017.1380920 · Cited by 15 · see citing works

Licochalcone A Inhibits Prostaglandin E2 by Targeting the MAPK Pathway in LPS Activated Primary Microglia

Bhatia, H. S., Apweiler, M., Sun, L., Baron, J., Tirkey, A., & Fiebich, B. L. (2023) · Molecules · doi:10.3390/molecules28041927 · Cited by 14 · see citing works

The role of infections and inflammation in schizophrenia: review of the evidence

Ahmed, G. K., Ramadan, H. K., Elbeh, K., & Haridy, N. A. (2024) · Middle East Current Psychiatry · doi:10.1186/s43045-024-00397-7 · Cited by 14 · see citing works

Inflammatory processes and schizophrenia: two independent lines of evidence from a study of twins discordant and concordant for schizophrenic disorders

Braun, S., Bridler, R., Müller, N., Schwarz, M., Seifritz, E., Weisbrod, M., Zgraggen, A., & Stassen, H. H. (2017) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-017-0792-z · Cited by 12 · see citing works

The role of the microbiota-gut-brain axis in schizophrenia: an immunological perspective

Su, B.-W., Li, Y., Yang, L.-Y., Yang, H., Wang, W., Ren, H., Bao, Y.-N., Lao, J.-Y., & Luan, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1711756 · Cited by 9 · see citing works

Effect of risperidone on serum IL-6 levels in individuals with schizophrenia: a systematic review and meta-analysis

Ramos-Méndez, M. Á., Tovilla‐Zárate, C. A., Juárez‐Rojop, I. E., Villar-Soto, M., Mendoza, A. D. G., González‐Castro, T. B., López‐Narváez, M. L., Martínez‐Magaña, J. J., Castillo-Ávila, R. G., & Villar-Juárez, G. E. (2022) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2022.2100264 · Cited by 7 · see citing works

Family-based association study of interleukin 10 (IL10) and interleukin 10 receptor alpha (IL10RA) functional polymorphisms in schizophrenia in Polish population

Kapelski, P., Skibińska, M., Maciukiewicz, M., Pawlak, J., Zaremba, D., & Hauser, J. (2016) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2016.05.010 · Cited by 7 · see citing works

From Schizophrenia Genetics to Disease Biology: Harnessing New Concepts and Technologies

Duan, J., Sanders, A. R., & Gejman, P. V. (2019) · Journal of Psychiatry and Brain Science · doi:10.20900/jpbs.20190014 · Cited by 8 · see citing works

Beyond dopamine: Exploring anti-inflammatory mechanisms of antipsychotics

Šafářová, N., Kolenič, M., & Španiel, F. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111459 · Cited by 6 · see citing works

Neuroinflammation. Contemporary anti-inflammatory treatment approaches

Al-Amin, M. M., & Reza, H. M. (2014) · Neurosciences · doi:10.17712/1658-3183.2066 · Cited by 6 · see citing works

Schizophrenia Pharmacology: Past, Present, and Future Targets for Intervention

Cronenwett, W. J. (2016) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20160009 · Cited by 6 · see citing works

Haloperidol Abrogates Matrix Metalloproteinase-9 Expression by Inhibition of NF-κB Activation in Stimulated Human Monocytic Cells

Lee, Y., Hsiao, C., Lin, F., Jan, J., Chou, Y.-C., Lin, Y.-Y., Chen, C.-K., Lam, K.-K., & Hsiao, G. (2018) · Mediators of Inflammation · doi:10.1155/2018/9541459 · Cited by 5 · see citing works

Cannabidiol reverses microglia activation and deficits of parvalbumin interneurons and their perineuronal nets in a MK-801-induced mouse model of schizophrenia

da Silva, N. R., Gobbo, D., Gomes, F. V., Scheller, A., Kirchhoff, F., Bel, E. D., & Guimarães, F. S. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149772 · Cited by 4 · see citing works

Immunomodulatory Effects of Antipsychotic Drugs in Whole Blood Cell Cultures from Healthy Subjects

Kim, E.-J., & Kim, Y. (2019) · Current Psychiatry Research and Reviews · doi:10.2174/2666082215666191018160333 · Cited by 4 · see citing works

Carotid surgery affects plasma kynurenic acid concentration: A pilot study

Dąbrowski, W. (2014) · Medical Science Monitor · doi:10.12659/msm.890212 · Cited by 4 · see citing works

Standardized extract of Ficus platyphylla reverses apomorphine-induced changes in prepulse inhibition and locomotor activity in rats

Chindo, B. A., Kahl, E., Trzeczak, D., Dehmel, P., Becker, A., & Fendt, M. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.06.044 · Cited by 3 · see citing works

Schizophrenia: One Coat of Many Colors

Smythies, J. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00043 · Cited by 2 · see citing works

Why is clozapine unique?

Bastiampillai, T. J., Govindasamy, J., Mohan, T. S., & Dhillon, R. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867413492225 · Cited by 2 · see citing works

Innate Immunity in Viral Encephalitis

Reiss, C. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-33189-8_8 · Cited by 2 · see citing works

Glial Cells in the Schizophrenia Puzzle: Angiotensin II Role

Occhieppo, V. B., Basmadjian, O. M., Marchese, N. A., Rodríguez, A., Jaime, A., Herrera, M., & Bregonzio, C. (2021) · Springer eBooks · doi:10.1007/978-3-030-61721-9_16 · Cited by 1 · see citing works

The Role of Interleukin-6 in the Pathological Mechanisms of Schizophrenia

Rukavishnikov, G. V., Zhilyaeva, T. V., Dubinin, E. E., & Mazo, G. E. (2023) · Neurochemical Journal · doi:10.1134/s1819712423010166 · Cited by 1 · see citing works

Interleukin-6 Role in Schizophrenia Pathological Mechanisms

Rukavishnikov, G. V., Zhilyaeva, T. V., Дубинина, Е. Е., & Mazo, G. E. (2023) · Нейрохимия · doi:10.31857/s1027813323010168 · Cited by 1 · see citing works

Application of edaravone-loaded nanogel in alleviating behavioral deficits and oxidative stress in schizophrenia rat model

Montazeri, S., Bijani, S., Rashidzadeh, H., Ramazani, A., Andalib, S., Kalantari‐Hesari, A., Cheraghi, G., & Hosseini, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-19312-z · Cited by 1 · see citing works

Estrés Oxidativo y Esquizofrenia

Prados, A. B. (2014) · doi:10.14201/gredos.124073

Anticorps anti-récepteur NMDA dans les premiers épisodes psychotiques

Guen, E. L. (2014) · HAL

Imaging the Host Response

Foss, C. A., Hammouda, N., Shen, C., Li, J., & Manning, H. C. (2017) · Springer eBooks · doi:10.1007/978-3-319-54592-9_5

Contemporary anti-inflammatory treatment approaches

Reza, H. M., & Al-Amin, M. M. (2014)

New Insights into the Molecular and Cellular Mechanism of Antipsychotics

Kim, S. H. (2019) · Journal of Korean Neuropsychiatric Association · doi:10.4306/jknpa.2019.58.1.12

Novel TSPO ligands to facilitate rapid tracer discovery and as precision imaging diagnostics of cancer

Li, J. (2016)

Mecanismos celulares e neuroquímicos do efeito tipo-antipsicótico do canabidiol: envolvimento dos receptores 5-HT1A e CB2

da Silva, N. R. (2021) · doi:10.11606/t.17.2021.tde-05112021-105109

Cytokines as Depression Underpinning

Zaydiner, B. (2022) · Pharmaceutics and Pharmacology Research · doi:10.31579/2693-7247/073

Bioactive and Inflammatory Markers in Emerging Psychotic Disorders

Berger, G. E. (2019) · Cambridge University Press eBooks · doi:10.1017/9781139839518.009

Dysregulation of Triptophan Hydroxylation and Oxidation Path in Schizophrenia and Effects on Cognitive Functions and Clinical SymptomsPreprint

Özmen, E. S., Arslan, F. C., Menteşe, A., Demir, S., Köksal, A. Ç., & Özmen, T. (2024) · Research Square · doi:10.21203/rs.3.rs-3851129/v1

Inflammation, infections et maladies mentales : identification de biomarqueurs et applications thérapeutiques potentielles

Fond, G. B. (2016) · theses.fr (ABES) · doi:10.70675/c6ecdda4z491cz4468zbdd6za65dbe62f0cb

Role of immune and nervous system interaction : pre-clinical and clinical studies

Daoudlarian, D. (2018) · doi:10.70675/77feff3azfefbz422az89bdzeafc45e09199

Dissecting first-episode psychosis heterogeneity with clustering analyses: A systematic review

Sperti, L., Pigoni, A., Nosari, G., Enrico, G., Torrente, Y., Brambilla, P., & Delvecchio, G. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106836

Immunologische Behandlungsoptionen bei schizophrenen Störungen

Müller, N., Krause, D., Weidinger, E., & Schwarz, M. (2014) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/s-0033-1355776 · Cited by 11 · see citing works

Immunological Treatment Options for Schizophrenia

Müller, N., Myint, A.-M., & Schwarz, M. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112800784826 · Cited by 34 · see citing works

Inflammation in Schizophrenia

Müller, N., Myint, A.-M., & Schwarz, M. (2012) · Advances in protein chemistry and structural biology · doi:10.1016/b978-0-12-398314-5.00003-9 · Cited by 84 · see citing works

Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects

Muller, N., Myint, A.-M., & J. Schwarz, M. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795049552 · Cited by 94 · see citing works

Beyond dopamine: Exploring anti-inflammatory mechanisms of antipsychotics

Šafářová, N., Kolenič, M., & Španiel, F. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111459 · Cited by 6 · see citing works